Population
Cell monolayer infected with herpes simplex virus-type 1
Comparison
Atropine (200 micrograms/ml) vs Control (untreated infected cells)
Design
Preclinical
Authors
Loading...
Hypothesis-generating for atropine in HSV-1; human trials needed before any clinical consideration.
Atropine demonstrates antiviral properties against herpes simplex virus-type 1 by preventing viral protein glycosylation, rendering newly formed virions noninfectious.
Alarcón et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: